Overview

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial with Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate Atopic Dermatitis in Adults
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vyne Therapeutics Inc.